SeaStar Medical Holding Corporation Warrant (ICUCW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ICUCW SEC filings page.
SeaStar Medical Holding Corporation Warrant (ICUCW) reported $1.7M in revenue over the twelve months to Jun 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financing inflows, not operating receipts, are carrying a still loss-making business through a sharp revenue expansion.
Revenue reached$1.2M in FY2025, but operating loss was still$12.2M ; the expansion therefore increased activity without yet producing operating leverage. This is a mismatch between top-line emergence and cost absorption, not evidence that gross economics are yet the primary bottleneck.
The near-fully gross margin is not the constraint: gross profit was
Operating cash flow was
Financial Health Signals
SeaStar Medical Holding Corporation Warrant does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
SeaStar Medical Holding Corporation Warrant passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
SeaStar Medical Holding Corporation Warrant reported a net loss of $12.2M while operations used $13.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
SeaStar Medical Holding Corporation Warrant reported an operating loss of $12.2M against $31K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
SeaStar Medical Holding Corporation Warrant generated $615K in revenue in Q2 2026. This represents an increase of 82.0% from the same quarter a year earlier. Against the prior quarter it is up 24.2%.
SeaStar Medical Holding Corporation Warrant reported -$3.7M in net income in Q2 2026. This represents a decrease of 86.3% from the same quarter a year earlier. Against the prior quarter it is down 5.9%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
SeaStar Medical Holding Corporation Warrant held $7.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
SeaStar Medical Holding Corporation Warrant's gross margin was 91.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.
SeaStar Medical Holding Corporation Warrant's ROE was -86.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 26.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 38.7 percentage points.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
SeaStar Medical Holding Corporation Warrant invested $2.5M in research and development in Q2 2026. This represents an increase of 143.0% from the same quarter a year earlier. Against the prior quarter it is up 7.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
ICUCW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $615K+82.0% | $495K+68.9% | $420K | $183K+169.1% | $338K | $293K | N/A | $68K |
| Cost of Revenue | $54K+100.0% | $46K | $12K | $14K | $27K | $0 | N/A | $0 |
| Gross Profit | $561K+80.4% | $449K+53.2% | $408K | $169K+148.5% | $311K | $293K | N/A | $68K |
| R&D Expenses | $2.5M+143.0% | $2.3M-3.6% | $2.2M | $1.9M-20.8% | $1.0M-55.6% | $2.4M+43.3% | N/A | $2.3M+114.9% |
| SG&A Expenses | $1.8M+77.9% | $1.7M+1.4% | $1.2M | $1.9M-13.3% | $1.0M-55.9% | $1.7M-25.3% | N/A | $2.2M+18.0% |
| Operating Income | -$3.8M-115.9% | -$3.6M+5.7% | -$3.0M | -$3.6M+19.7% | -$1.8M+62.4% | -$3.8M+3.2% | N/A | -$4.5M-51.5% |
| Interest Expense | $8K-11.1% | $6K-45.5% | $11K | $0-100.0% | $9K-89.0% | $11K-92.3% | N/A | $272K+21.4% |
| Income Tax | $0 | $3K0.0% | $0 | $0 | $0-100.0% | $3K | N/A | $0 |
| Net Income | -$3.7M-86.3% | -$3.5M+6.7% | -$2.9M | -$3.5M+22.5% | -$2.0M+38.1% | -$3.8M+70.3% | N/A | -$4.5M+38.1% |
| EPS (Basic) | -$0.91+48.6% | -$0.90+79.5% | -$5.26+91.3% | -$0.13+88.2% | -$1.77-71.8% | -$4.38+7.4% | -$60.23-37543.8% | -$1.10+87.8% |
| EPS (Diluted) | N/A | N/A | N/A | N/A | -$0.18 | -$0.44 | -$0.53 | -$1.10 |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | 11M | 9M | N/A | 4M |
Not reported in any period shown, so not listed: EBITDA.
ICUCW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.6M+3.2% | $11.3M-20.7% | $14.2M+204.0% | $15.5M+238.6% | $8.4M+141.8% | $14.2M+83.5% | $4.7M+32.6% | $4.6M+82.9% |
| Current Assets | $8.2M+7.6% | $10.8M+58.7% | $13.6M+260.6% | $14.9M+311.3% | $7.6M+216.8% | $6.8M+3.8% | $3.8M+63.2% | $3.6M+195.2% |
| Cash & Equivalents | $7.0M+10.4% | $9.3M+76.5% | $12.0M+558.6% | $13.8M+561.0% | $6.3M+434.5% | $5.3M+5.5% | $1.8M+933.5% | $2.1M+2752.1% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $77K0.0% | $57K+29.5% | $66K | $83K | $77K | $44K | $0 | $0 |
| Accounts Receivable | $208K-4.1% | $179K+62.7% | $237K+111.6% | $221K+225.0% | $217K | $110K | $112K | $68K |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $4.4M-13.7% | $3.9M-71.0% | $3.7M-45.3% | $4.1M-11.4% | $5.0M-51.4% | $13.6M+11.6% | $6.8M-60.6% | $4.6M-75.2% |
| Current Liabilities | $4.4M-13.7% | $3.9M-43.9% | $3.7M-45.3% | $4.1M | $5.0M-49.2% | $7.0M-27.1% | $6.8M-47.6% | N/A |
| Non-Current Liabilities | $0 | $0-100.0% | $0 | $0+100.0% | $0-100.0% | $6.6M+157.4% | $0-100.0% | -$2.0M-135.8% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Total Equity | $4.3M+28.6% | $7.3M+1194.7% | $10.4M+577.1% | $11.5M+558774.5% | $3.3M+148.4% | $565K+112.6% | -$2.2M+84.3% | -$2K+100.0% |
| Retained Earnings | -$159.0M-9.4% | -$155.2M-8.3% | -$151.7M-8.7% | -$148.8M-10.1% | -$145.3M-11.2% | -$143.3M-12.5% | -$139.6M-21.6% | -$135.1M-28.4% |
Not reported in any period shown, so not listed: Goodwill.
ICUCW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.0M+0.4% | -$2.8M-4.0% | -$4.1M+12.8% | -$3.8M+23.2% | -$3.0M-6.5% | -$2.7M+23.9% | -$4.7M-4.6% | -$5.0M-274.1% |
| Stock-Based Compensation | -$99K-202.1% | $91K-45.5% | N/A | $290K+45.0% | $97K+136.6% | $167K-61.5% | N/A | $200K-58.7% |
| Financing Cash Flow | $605K-84.9% | $129K-97.9% | $2.3M-47.8% | $11.3M+91.4% | $4.0M+495.0% | $6.1M-26.4% | $4.4M-3.4% | $5.9M+322.7% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
ICUCW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.2%-0.8pp | 90.7%-9.3pp | 97.1% | 92.3%-7.7pp | 92.0% | 100.0% | N/A | 100.0% |
| Operating Margin | -616.4% | -727.9% | -718.6% | -1955.7% | -519.5% | -1304.4% | N/A | -6552.9% |
| Net Margin | -606.5% | -711.3% | -691.4% | -1897.3% | -592.3% | -1287.4% | N/A | -6585.3% |
| Return on Equity | -86.8%-26.9pp | -48.1%+619.5pp | -27.9% | -30.3% | -59.9% | -667.6% | N/A | N/A |
| Return on Assets | -43.1%-19.3pp | -31.3%-4.7pp | -20.5% | -22.4%+75.3pp | -23.9%+69.5pp | -26.6%+137.5pp | N/A | -97.7%+190.7pp |
| Current Ratio | 1.89+0.4x | 2.73+1.8x | 3.63+3.1x | 3.66 | 1.52+1.3x | 0.96+0.3x | 0.55+0.4x | N/A |
| Debt-to-Equity | 1.01-0.5x | 0.54-23.6x | 0.36 | 0.35 | 1.51 | 24.13 | N/A | N/A |
| Asset Turnover | 0.070.0x | 0.040.0x | 0.03 | 0.010.0x | 0.040.0x | 0.020.0x | N/A | 0.010.0x |
Not reported in any period shown, so not listed: FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Where SeaStar Medical Holding Corporation Warrant Ranks
Frequently Asked Questions
What is SeaStar Medical Holding Corporation Warrant's annual revenue?
SeaStar Medical Holding Corporation Warrant (ICUCW) reported $1.2M in total revenue for fiscal year 2025. This represents a 814.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is SeaStar Medical Holding Corporation Warrant's revenue growing?
SeaStar Medical Holding Corporation Warrant (ICUCW) revenue grew by 814.1% year-over-year, from $135K to $1.2M in fiscal year 2025.
Is SeaStar Medical Holding Corporation Warrant profitable?
No, SeaStar Medical Holding Corporation Warrant (ICUCW) reported a net income of -$12.2M in fiscal year 2025.
What is SeaStar Medical Holding Corporation Warrant's gross margin?
SeaStar Medical Holding Corporation Warrant (ICUCW) had a gross margin of 95.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is SeaStar Medical Holding Corporation Warrant's return on equity (ROE)?
SeaStar Medical Holding Corporation Warrant (ICUCW) has a return on equity of -116.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is SeaStar Medical Holding Corporation Warrant's operating cash flow?
SeaStar Medical Holding Corporation Warrant (ICUCW) recorded an outflow of $13.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are SeaStar Medical Holding Corporation Warrant's total assets?
SeaStar Medical Holding Corporation Warrant (ICUCW) had $14.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does SeaStar Medical Holding Corporation Warrant spend on research and development?
SeaStar Medical Holding Corporation Warrant (ICUCW) invested $7.5M in research and development during fiscal year 2025.
What is SeaStar Medical Holding Corporation Warrant's current ratio?
SeaStar Medical Holding Corporation Warrant (ICUCW) had a current ratio of 3.63 as of fiscal year 2025, which is generally considered healthy.
What is SeaStar Medical Holding Corporation Warrant's debt-to-equity ratio?
SeaStar Medical Holding Corporation Warrant (ICUCW) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is SeaStar Medical Holding Corporation Warrant's return on assets (ROA)?
SeaStar Medical Holding Corporation Warrant (ICUCW) had a return on assets of -85.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does SeaStar Medical Holding Corporation Warrant's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, SeaStar Medical Holding Corporation Warrant (ICUCW) held $12.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $13.6M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is SeaStar Medical Holding Corporation Warrant's Piotroski F-Score?
SeaStar Medical Holding Corporation Warrant (ICUCW) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are SeaStar Medical Holding Corporation Warrant's earnings high quality?
SeaStar Medical Holding Corporation Warrant (ICUCW) reported a net loss of $12.2M while operations used $13.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can SeaStar Medical Holding Corporation Warrant cover its interest payments?
SeaStar Medical Holding Corporation Warrant (ICUCW) reported an operating loss of $12.2M against $31K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.